Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Trifluoroacetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 known ✓ | P30926 | 2/20 | 0.34 |
| ▸ | CHRNA3 known ✓ | P32297 | 2/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.32 |
| ▸ | LCK | P06239 | 1/20 | 0.32 |
| ▸ | FYN | P06241 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL34467355 | 0.80 | SLC6A2 (0.35) | CHRNB2CHRNB4CHRNA3CHRNA4SLC6A2 | |
| Trifluoroacetic Acid SCHEMBL928724 | 0.78 | CCR5 (0.47) | CHRNB2CHRNB4CHRNA3CHRNA4SLC6A2 | |
| Trifluoroacetic Acid SCHEMBL2895465 | 0.78 | CHRNA7 (0.36) | CHRNB2CHRNB4CHRNA3CHRNA4SLC6A2 | |
| Trifluoroacetic Acid SCHEMBL4831016 | 0.78 | CCR5 (0.47) | CHRNB2CHRNB4CHRNA3CHRNA4SLC6A2 | |
| Trifluoroacetic Acid SCHEMBL48017 | 0.78 | MAN1B1 (0.36) | SLC6A2SLC6A4SLC6A3CHRNA7CYP1A2 | |
| Trifluoroacetic Acid SCHEMBL30496656 | 0.77 | CYP2D6 (0.33) | CHRNB2CHRNA3CHRNA4SLC6A2SLC6A4 | |
| Trifluoroacetic Acid SCHEMBL1977391 | 0.77 | FFAR3 (0.54) | CYP2D6CYP2C19FFAR3LCKFYN | |
| Trifluoroacetic Acid SCHEMBL5242831 | 0.77 | FFAR3 (0.54) | CYP2D6CYP2C19FFAR3LCKFYN | |
| Trifluoroacetic Acid SCHEMBL30619382 | 0.77 | FFAR3 (0.54) | CYP2D6CYP2C19FFAR3LCKFYN | |
| Trifluoroacetic Acid SCHEMBL479935 | 0.77 | FFAR3 (0.54) | CYP2D6CYP2C19FFAR3LCKFYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230061736-A1 | GPR119 AGONISTS | KALLYOPE, INC. | 2023-03-02 | — | — | US | disclosed |
| US-11339165-B2 | Pyrazolopyrimidines having activity against the respiratory syncytial virus (RSV) | Janssen Sciences Ireland Unlimited Company (IE) | 2022-05-24 | — | — | US | disclosed |
| US-20220153719-A1 | GPR119 AGONISTS | KALLYOPE, INC. | 2022-05-19 | — | — | US | disclosed |
| WO-2021071837-A1 | GPR119 AGONISTS | KALLYOPE, INC. (US) | 2021-04-15 | — | — | WO | disclosed |
| US-20200361942-A1 | PYRAZOLOPYRIMIDINES HAVING ACTIVITY AGAINST THE RESPIRATORY SYNCYTIAL VIRUS (RSV) | Janssen Sciences Ireland Unlimited Company (IE) | 2020-11-19 | — | — | US | disclosed |
| EP-3717486-A1 | PYRAZOLOPYRIMIDINES HAVING ACTIVITY AGAINST THE RESPIRATORY SYNCYTIAL VIRUS (RSV) | Janssen Sciences Ireland Unlimited Company (IE) | 2020-10-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200361942-A1 | PYRAZOLOPYRIMIDINES HAVING ACTIVITY AGAINST THE RESPIRATORY SYNCYTIAL VIRUS (RSV) | RRP15, MAVS, ACE | CHRNB4 4680/4885CHRNA3 4747/4885CHRNB2 4787/4885 |
| US-11339165-B2 | Pyrazolopyrimidines having activity against the respiratory syncytial virus (RSV) | RRP15, MAVS, ACE | CHRNB4 4680/4885CHRNA3 4747/4885CHRNB2 4787/4885 |
| US-20230061736-A1 | GPR119 AGONISTS | GPR119, GLP1R, GCGR | CHRNB4 459/4885CHRNA3 352/4885CHRNB2 412/4885 |
| US-20220153719-A1 | GPR119 AGONISTS | GPR119, GLP1R, GCGR | CHRNB4 459/4885CHRNA3 352/4885CHRNB2 412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.